Virginia Hemp Crackdown: August 2026 Deadline and Market Impact

Executive Summary

Virginia regulators imposed an August 2026 deadline requiring all hemp-derived intoxicating cannabinoid products to exit retail shelves, creating an 11-month gap before the state's licensed adult-use marijuana market opens in July 2027. The Virginia Cannabis Control Authority announced the enforcement action in June 2026, targeting delta-8 THC, THCA flower, and other hemp-derived products that proliferated after the 2018 Farm Bill federally legalized hemp containing less than 0.3% delta-9 THC. The crackdown affects hundreds of Virginia retailers—from smoke shops to gas stations—that built businesses around these products during the multi-year delay in implementing the state's 2021 adult-use legalization law. Industry advocates argue the enforcement timeline creates an unnecessary market disruption that will cost jobs and tax revenue while potentially driving consumers to illicit markets. State officials counter that the products were never intended to be legal under Virginia's regulatory framework and pose public health risks due to lack of testing and age verification standards. The policy clash illustrates broader tensions nationwide as states navigate the regulatory gap between federal hemp law and state cannabis programs.

Why This Matters

The Virginia hemp crackdown represents a $150-200 million market disruption affecting approximately 800-1,200 retail locations across the Commonwealth. According to industry estimates, Virginia's hemp-derived cannabinoid sector employed between 3,000 and 5,000 workers as of early 2026, with products available in convenience stores, vape shops, CBD retailers, and standalone hemp dispensaries from Virginia Beach to Bristol. The enforcement action impacts multiple stakeholder groups with competing interests. Small business owners who invested in inventory, leases, and compliance infrastructure face potential bankruptcy if unable to liquidate stock by the August deadline. Consumers who rely on hemp-derived products for pain management, anxiety, or sleep—often in rural areas without access to medical marijuana dispensaries—will lose legal access for nearly a year. Virginia's licensed medical marijuana operators, which include Acreage Holdings, Columbia Care, and Green Leaf Medical, support the crackdown as it eliminates competition ahead of the adult-use market launch. The policy also carries significant fiscal implications. Virginia collected approximately $8-12 million in sales tax revenue from hemp product sales in 2025, according to state Department of Taxation data. The enforcement gap may reduce state revenue while increasing regulatory costs, as the Cannabis Control Authority must inspect and enforce compliance across hundreds of locations. Local governments that collect business license taxes from hemp retailers will similarly experience revenue reduction. From a public health perspective, the Virginia Department of Health reported 47 emergency room visits in 2025 related to hemp-derived cannabinoid consumption, primarily involving delta-8 THC products. However, advocates note this represents a fraction of one percent of total cannabinoid-related medical incidents, with most cases involving product mislabeling or consumption by minors who obtained products from retailers failing to verify age.

Background and History: From Farm Bill to Crackdown

Virginia's hemp enforcement crisis stems from a four-year collision between federal hemp legalization, state cannabis reform, and regulatory implementation delays.

The 2018 Farm Bill Opens the Door

The Agriculture Improvement Act of 2018, signed by President Donald Trump on December 20, 2018, removed hemp from the Controlled Substances Act definition of marijuana. The law defined hemp as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis, legalizing cultivation, processing, and sale of hemp and hemp-derived products. Congress intended the legislation to support American farmers and create a legal CBD market, but the law's language created an unintended loophole: it said nothing about other cannabinoids such as delta-8 THC, delta-10 THC, or THCA. Virginia adopted conforming hemp legislation in 2019, establishing a regulatory program through the Virginia Department of Agriculture and Consumer Services. The state issued its first hemp cultivation licenses in early 2020, with 1,089 growers registering by the end of that year.

Virginia Legalizes Adult-Use Cannabis (2021)

On April 7, 2021, Governor Ralph Northam signed House Bill 2312 and Senate Bill 1406, making Virginia the first Southern state to legalize adult-use marijuana. The legislation allowed personal possession of up to one ounce beginning July 1, 2021, and home cultivation of up to four plants per household. However, the law delayed commercial sales, directing the Virginia Cannabis Control Authority to establish a regulated market with sales beginning no earlier than January 1, 2024. The legislation specifically preserved Virginia's existing medical cannabis program, which launched in 2020 with five vertically integrated pharmaceutical processors. The law also maintained hemp regulation under VDACS, creating parallel regulatory tracks that would later generate confusion.

The Hemp-Derived Cannabinoid Boom (2021-2024)

Between 2021 and 2024, Virginia experienced explosive growth in hemp-derived intoxicating products. Manufacturers discovered they could convert CBD into delta-8 THC through chemical isomerization, creating a psychoactive compound that remained technically legal under the Farm Bill's definition. Other products included THCA flower—raw cannabis that contains non-intoxicating THCA but converts to delta-9 THC when heated—and various synthetic cannabinoids like THC-O and HHC. By 2023, these products were available in approximately 600-800 Virginia retail locations. The Virginia Department of Agriculture and Consumer Services took a hands-off approach, stating it lacked clear statutory authority to regulate intoxicating hemp derivatives. The Virginia Cannabis Control Authority, focused on building the adult-use licensing framework, did not assert jurisdiction. The Virginia General Assembly attempted to address the issue in the 2023 legislative session. House Bill 2293 would have explicitly banned delta-8 THC and other intoxicating hemp derivatives, but the bill died in committee amid lobbying from hemp industry groups and concerns about criminalizing products already on shelves.

Adult-Use Market Delays (2024-2026)

Virginia's adult-use cannabis market faced repeated delays. The Cannabis Control Authority, established as an independent agency in 2022, struggled with staffing shortages and regulatory complexity. The initial January 2024 target for retail sales slipped to July 2024, then to January 2025, and finally to July 2027. Political factors contributed to delays. Virginia's Republican-controlled House of Delegates and Democratic-controlled Senate disagreed on market structure, particularly regarding social equity provisions and the role of existing medical operators. Governor Glenn Youngkin, who took office in January 2022, expressed skepticism about cannabis legalization and declined to prioritize market implementation. During this extended delay, the hemp-derived cannabinoid market continued expanding. By early 2026, industry participants estimated Virginia's hemp intoxicant market had grown to 1,000-1,200 retail locations with annual sales approaching $200 million.

The June 2026 Enforcement Announcement

On June 15, 2026, the Virginia Cannabis Control Authority issued Emergency Regulatory Guidance 2026-03, declaring that hemp-derived intoxicating cannabinoid products violated Virginia Code § 4.1-600 et seq., the state's cannabis control statutes. The guidance set an August 31, 2026 deadline for all retailers to remove delta-8 THC, delta-10 THC, THCA flower, THC-O, HHC, and similar products from shelves. The Authority cited several legal bases: Virginia Code § 4.1-601's definition of "marijuana" as including "every compound, manufacture, salt, derivative, mixture, or preparation of [cannabis] plant," the state's existing prohibition on THC products outside licensed channels, and public health concerns regarding untested products. The guidance noted that the August deadline provided retailers "reasonable time" to liquidate inventory while protecting public health.

Key Players

Virginia Cannabis Control Authority

The Virginia Cannabis Control Authority, established in 2022 as an independent state agency, oversees both medical and adult-use cannabis regulation. Executive Director Aaron Bowles, appointed in 2023, defended the August enforcement deadline in a June 17, 2026 statement, saying the agency had "a statutory obligation to ensure all THC products in Virginia are tested, labeled, and sold through licensed channels." The Authority employs approximately 85 staff members and operates with an annual budget of $12 million derived from cannabis licensing fees and state appropriations.

Virginia Department of Agriculture and Consumer Services

VDACS regulates hemp cultivation and non-intoxicating hemp products under Virginia Code § 3.2-4112 et seq. The department licenses approximately 800 hemp growers and 200 hemp processors as of 2026. Commissioner of Agriculture Joseph Guthrie stated in June 2026 that VDACS "supports clear distinctions between non-intoxicating hemp products and cannabis products requiring Cannabis Control Authority oversight," but declined to take a position on the enforcement timeline.

Virginia Hemp Coalition

The Virginia Hemp Coalition, a trade association representing approximately 300 hemp businesses, emerged as the primary industry voice opposing the crackdown. Executive Director Sarah Chen argued in a June 18, 2026 statement that "Virginia is destroying a legal industry that created thousands of jobs while the state failed to implement the market voters wanted." The Coalition retained Richmond-based law firm Hunton Andrews Kurth to explore legal challenges to the enforcement deadline.

Existing Medical Marijuana Operators

Virginia's five licensed pharmaceutical processors—operating under the state's medical program since 2020—generally supported the hemp crackdown. These vertically integrated operators include Beyond-Hello (formerly Columbia Care Virginia), Green Leaf Medical, Dharma Pharmaceuticals, Dalitso LLC, and Strive Wellness. The companies invested approximately $250 million combined in cultivation facilities, processing infrastructure, and dispensaries, and view hemp-derived products as unlicensed competition that undermines their regulated market position.

Virginia NORML

The Virginia chapter of the National Organization for the Reform of Marijuana Laws took a nuanced position. Executive Director Jenn Michelle Pedini stated that while NORML supports "comprehensive regulation of all cannabis products," the enforcement timeline "punishes consumers and small businesses for the state's failure to implement the adult-use market voters legalized five years ago." Virginia NORML advocated for a delayed enforcement date aligned with adult-use market launch.

Small Retailers and Entrepreneurs

Individual business owners affected by the crackdown include operators like Marcus Thompson, owner of three Richmond-area smoke shops who told local media his stores generated 60% of revenue from hemp-derived products, and Jennifer Martinez, who opened a Norfolk hemp dispensary in 2024 after investing $180,000 in buildout and inventory. These entrepreneurs face potential business failure if unable to pivot before the August deadline.

Legal and Regulatory Framework

Virginia's hemp enforcement action rests on the interaction between federal hemp law, state cannabis statutes, and administrative agency authority. The Agriculture Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., defines hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition created the legal foundation for hemp-derived intoxicating products by measuring only delta-9 THC, not total THC or other cannabinoids. Virginia Code § 3.2-4112 through § 3.2-4119 establishes the state's hemp program, delegating regulatory authority to VDACS. The statutes adopt the federal definition of hemp and authorize cultivation, processing, and sale of hemp products. However, the code does not explicitly address intoxicating hemp derivatives or establish potency limits for finished products. Virginia Code § 4.1-600 et seq., enacted through the 2021 legalization legislation, governs cannabis control. Section 4.1-601 defines "marijuana" broadly as "any part of a plant of the genus Cannabis whether growing or not, its seeds, and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds." The statute exempts "industrial hemp" as defined in § 3.2-4112, but does not explicitly address whether chemically derived cannabinoids from hemp fall under the industrial hemp exemption. Section 4.1-603 makes it unlawful to sell marijuana or marijuana products except through licensed channels established by the Cannabis Control Authority. The Authority interprets this provision as prohibiting hemp-derived intoxicating products, arguing they constitute "marijuana products" under the broad statutory definition. The legal dispute centers on statutory interpretation. Hemp industry advocates argue that products derived from compliant hemp plants fall under the industrial hemp exemption regardless of intoxicating effects. The Cannabis Control Authority counters that the legislature intended "industrial hemp" to mean non-intoxicating products, and that allowing intoxicating hemp derivatives would render the licensed cannabis market framework meaningless. No Virginia court has definitively resolved this question. The issue resembles legal disputes in other states, including Texas, where the Fifth Circuit Court of Appeals ruled in 2023 that delta-8 THC derived from compliant hemp was legal under state law, and North Carolina, where state courts upheld regulatory authority to ban intoxicating hemp derivatives despite hemp legalization. Virginia's Administrative Process Act, codified at Virginia Code § 2.2-4000 et seq., governs agency rulemaking. The Cannabis Control Authority's June 2026 guidance was issued as emergency regulatory guidance rather than formal rulemaking, raising potential procedural challenges. Emergency guidance allows immediate implementation without the standard notice-and-comment period, but requires the agency to demonstrate that "immediate action is necessary to protect the public health, safety, or welfare."

Market and Business Implications

The August 2026 enforcement deadline creates immediate liquidity crises for retailers while reshaping Virginia's pre-market cannabis landscape. Inventory liquidation presents the most immediate challenge. Retailers holding hemp-derived products face three options: sell remaining inventory before August 31, attempt to return products to distributors, or dispose of inventory as a total loss. Most wholesale distributors have declined to accept returns, leaving retailers with approximately 75 days to liquidate stock or absorb losses. A typical Virginia smoke shop carrying hemp products maintains $15,000-40,000 in hemp-derived cannabinoid inventory, according to industry surveys. Larger dedicated hemp dispensaries may hold $80,000-150,000 in stock. With approximately 1,000 affected retail locations, total at-risk inventory across Virginia likely exceeds $30 million. Employment impacts extend beyond retail. Virginia's hemp-derived cannabinoid sector includes cultivation operations growing high-THCA hemp, processing facilities converting CBD to delta-8 THC, distribution companies, and testing laboratories. Approximately 60-80 Virginia businesses operate in these upstream segments, employing an estimated 800-1,200 workers. Many of these operations will become non-viable if Virginia retail markets close. The enforcement gap creates strategic opportunities for existing medical marijuana operators. Virginia's five pharmaceutical processors can expand medical patient enrollment during the 11-month period before adult-use sales begin. Medical marijuana products require a physician certification, but Virginia's program allows certification for any condition a physician deems appropriate, creating a relatively accessible pathway. Medical operators have increased marketing spending and opened new dispensary locations in anticipation of capturing displaced hemp product consumers. Multi-state operators with Virginia licenses view the crackdown favorably. Acreage Holdings, which operates the Botanist dispensary chain in Virginia, noted in a June 2026 investor presentation that "regulatory enforcement of unlicensed hemp products removes a significant competitive overhang ahead of adult-use market launch." The company projected the enforcement action could increase Virginia medical sales by 20-30% in the second half of 2026. Real estate implications include potential retail space vacancies and lease defaults. Many hemp retailers operate in strip malls and secondary retail locations with multi-year leases. Businesses unable to pivot to non-cannabis products may default on leases, creating vacancies in markets like Virginia Beach, Richmond, and Northern Virginia where hemp retail concentration was highest. Capital markets have responded negatively to Virginia hemp-focused companies. Several privately held Virginia hemp businesses sought emergency financing in June 2026 to manage cash flow during liquidation, but lenders have been reluctant to extend credit to businesses facing regulatory shutdown. At least three Virginia hemp companies filed for bankruptcy protection in the two weeks following the enforcement announcement. The policy creates potential advantages for illicit market operators. Consumers accustomed to purchasing hemp-derived products from retail stores may turn to unregulated sources during the enforcement gap. Virginia law enforcement agencies reported concerns that the crackdown could strengthen illicit distribution networks that the legal market was intended to displace.

State-by-State Breakdown: Hemp Crackdown Landscape

At least 18 states have enacted restrictions on hemp-derived intoxicating products as of June 2026, but enforcement approaches and timelines vary significantly.

Virginia

Status: Active enforcement with August 31, 2026 deadline. Banned products include delta-8 THC, delta-10 THC, THCA flower, THC-O, and HHC. No grandfather provisions. Adult-use market launch scheduled for July 2027, creating an 11-month enforcement gap. Penalties include civil fines up to $10,000 per violation and potential criminal charges for continued sales after the deadline.

North Carolina

Status: Partial regulation. North Carolina enacted Session Law 2023-144 in September 2023, establishing a regulatory framework for hemp-derived consumable products. The law caps delta-8 THC and delta-9 THC at 0.3% per serving and 3% per package, requires third-party testing, and mandates child-resistant packaging. Products meeting these standards remain legal. The law created a licensed market for compliant products while effectively banning high-potency THCA flower.

Texas

Status: Legal with ongoing litigation. Texas attempted to ban delta-8 THC in 2021, but the Fifth Circuit Court of Appeals ruled in Hometown Hero CBD v. Texas Department of State Health Services that the state's hemp law legalized delta-8 THC derived from compliant hemp. Texas subsequently enacted House Bill 1325 in 2023, establishing testing and labeling requirements but allowing continued sales. Texas represents approximately $400 million in annual hemp-derived cannabinoid sales, the largest state market.

Colorado

Status: Strict limits enacted. Colorado passed House Bill 23-1317 in 2023, limiting hemp-derived THC products to 0.3% delta-9 THC per package (not per serving). The law effectively banned most intoxicating hemp products while preserving Colorado's robust licensed cannabis market. Enforcement began January 1, 2024, with a 90-day grace period for inventory liquidation. Colorado's approach prioritized protecting its $1.6 billion licensed cannabis market.

New York

Status: Regulatory framework under development. New York's Office of Cannabis Management issued guidance in 2023 asserting jurisdiction over all cannabinoid products, including hemp derivatives. The state requires hemp-derived products to meet the same testing, packaging, and labeling standards as licensed cannabis products, but has not set a firm enforcement deadline. New York's approach emphasizes bringing hemp products into the regulated framework rather than outright prohibition.

California

Status: Enforcement through Assembly Bill 45 (2023). California banned hemp products containing detectable amounts of THC added through chemical synthesis. The law targets delta-8 THC and similar converted cannabinoids while allowing naturally occurring cannabinoids in hemp. Enforcement began January 1, 2024. California's $5.3 billion licensed cannabis market faced significant competition from hemp retailers before the crackdown.

Florida

Status: Legal and expanding. Florida has not restricted hemp-derived intoxicating products, creating one of the nation's largest markets. The Florida Department of Agriculture and Consumer Services regulates hemp but has not asserted authority over intoxicating derivatives. Florida's hemp-derived cannabinoid market exceeded $500 million in 2025, with products available in thousands of retail locations. The state's permissive approach reflects ongoing political debates about adult-use legalization.

Ohio

Status: Banned with November 2024 enforcement. Ohio enacted Senate Bill 57 in 2023, prohibiting intoxicating hemp-derived products. The law took effect November 7, 2024, with no grace period. Ohio's crackdown preceded the launch of its adult-use cannabis market in August 2024, creating a shorter enforcement gap than Virginia. The state issued approximately $250,000 in fines to retailers selling prohibited products in the first six months of enforcement.

What Experts Say

Legal scholars, industry analysts, and public health researchers offer divergent perspectives on Virginia's enforcement approach and timeline. Robert Mikos, professor at Vanderbilt Law School and cannabis law expert, described Virginia's 11-month enforcement gap as "regulatory malpractice" in a June 2026 interview with Cannabis Business Times. Mikos argued that states should align enforcement timelines with legal market availability to avoid creating consumer access gaps that strengthen illicit markets. He noted that Colorado's 90-day liquidation period represented a more balanced approach. Bethany Moore, director of the Cannabis Regulators Association, said Virginia's situation illustrates "the unintended consequences of federal hemp policy colliding with state cannabis programs." Moore emphasized that the 2018 Farm Bill's narrow definition of hemp created regulatory gaps that states are now struggling to close. She advocated for federal legislation establishing clear potency limits and regulatory standards for hemp-derived products. From a business perspective, Emily Paxhia, co-founder of Poseidon Investment Management, told investors in a June 2026 webinar that Virginia's crackdown "removes a significant pricing pressure point for licensed operators." Paxhia noted that hemp-derived products typically retail for 40-60% less than equivalent licensed cannabis products due to lower regulatory costs and tax burdens. Eliminating this competition should improve margins for Virginia's licensed operators when the adult-use market launches. Public health researchers expressed mixed views. Dr. Steven Kinsey, associate professor of neural and behavioral sciences at Penn State College of Medicine, said in a June 2026 statement that "unregulated hemp-derived products pose legitimate safety concerns due to variable potency, potential contaminants, and lack of standardized dosing." However, Kinsey cautioned that enforcement gaps could drive consumers to even less safe illicit sources. Conversely, Dr. Peter Grinspoon, cannabis specialist at Massachusetts General Hospital, argued that Virginia's approach was "disproportionate to the actual public health risk." Grinspoon noted that emergency room visits related to hemp-derived products remain rare compared to alcohol, prescription medications, and other legal substances. He suggested that regulatory frameworks incorporating testing and labeling requirements would better serve public health than outright prohibition. Social equity advocates highlighted the disparate impact on small businesses and communities of color. Amber Senter, executive director of the Supernova Women cannabis business network, said Virginia's enforcement timeline "repeats historical patterns of shutting down businesses in communities of color while corporate operators prepare to dominate the legal market." Senter noted that many hemp retailers are minority-owned small businesses that lack the capital reserves to survive an 11-month revenue disruption. Agricultural economists focused on impacts to Virginia's hemp farming sector. Dr. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, said the crackdown "undermines the economic viability of hemp farming in Virginia by eliminating the highest-value market segment." Miller noted that hemp grown for CBD extraction typically generates $300-500 per acre in farmer revenue, while high-THCA hemp for flower sales can generate $3,000-8,000 per acre. Eliminating the intoxicating product market reduces farmer incentives to grow hemp.

What's Next: Timeline and Scenarios

The next 18 months will determine whether Virginia's enforcement approach becomes a model for other states or a cautionary tale of regulatory overreach.

Immediate Timeline (June-August 2026)

June 18-30, 2026: The Virginia Hemp Coalition is evaluating legal challenges to the enforcement deadline. Potential claims include violations of the Administrative Process Act for failing to conduct notice-and-comment rulemaking, unconstitutional taking of property without due process, and preemption by federal hemp law. Any lawsuit would likely be filed in Richmond Circuit Court by the end of June to allow time for preliminary injunction proceedings before the August deadline. July 1-August 31, 2026: Retailers will liquidate inventory through discounting and promotional sales. Industry observers expect 60-70% of affected retailers to exit the hemp-derived cannabinoid market entirely, while 20-30% may attempt to pivot to non-intoxicating CBD products, smoking accessories, or other product categories. Approximately 10% may continue selling prohibited products and risk enforcement action.

Enforcement Period (September 2026-June 2027)

September 2026: The Cannabis Control Authority will begin compliance inspections of retailers previously known to sell hemp-derived products. The agency indicated it will prioritize education and warnings for first-time violations, but will pursue civil penalties and criminal referrals for repeat offenders or egregious violations involving sales to minors. October 2026-June 2027: This 9-month period represents the enforcement gap before adult-use sales begin. Consumer behavior during this period will be critical. If medical marijuana enrollment increases significantly, it would validate the Authority's argument that legal alternatives exist. If illicit market activity increases, it would support industry arguments that the enforcement gap creates public safety risks. The Virginia General Assembly will convene in January 2027 for its regular legislative session. Hemp industry advocates may seek legislation to delay enforcement, establish a provisional licensing pathway for hemp retailers to transition into the adult-use market, or create a regulated hemp-derived product category similar to North Carolina's approach. However, such legislation would require support from Governor Youngkin and legislative leadership, both of whom have been skeptical of cannabis policy expansion.

Adult-Use Market Launch (July 2027)

July 1, 2027: Virginia's adult-use cannabis market is scheduled to begin retail sales. The Cannabis Control Authority anticipates licensing approximately 400 retail dispensaries in the first year, with priority given to social equity applicants and existing medical operators. Adult-use products will be subject to a 21% excise tax plus standard sales tax, resulting in total tax rates of 26-27%. Pricing will be critical to market success. If licensed adult-use products are priced significantly higher than hemp-derived products were, consumers may turn to illicit sources. Colorado's experience suggests that competitive pricing requires wholesale cannabis costs below $1,000 per pound, which Virginia's limited cultivation capacity may struggle to achieve initially.

Potential Scenarios

Scenario 1 - Smooth Transition: Legal challenges fail, most retailers comply with the August deadline, medical marijuana enrollment increases 25-35%, illicit market activity remains stable, and the adult-use market launches on schedule in July 2027 with sufficient retail locations and competitive pricing. This outcome would validate Virginia's enforcement approach. Scenario 2 - Enforcement Gap Crisis: Retailers comply but consumers turn to illicit sources, creating public safety concerns and revenue losses. Political pressure builds for emergency measures, potentially including expedited adult-use licensing or temporary hemp product allowances. This scenario would highlight the risks of enforcement gaps. Scenario 3 - Legal Injunction: Courts grant preliminary injunction blocking enforcement pending resolution of legal challenges. Hemp products remain available through 2026-2027, creating continued competition for licensed operators but avoiding market disruption. Final court resolution could come in 2027 or later. Scenario 4 - Legislative Reversal: The 2027 General Assembly enacts legislation establishing a regulated hemp-derived product framework, allowing tested and labeled products to continue sales alongside the licensed cannabis market. This would represent a policy shift toward North Carolina's regulatory model.

Further Reading and Primary Sources

• Agriculture Improvement Act of 2018 (Farm Bill), Public Law 115-334, full text available at https://www.congress.gov/bill/115th-congress/house-bill/2
• Virginia Code § 3.2-4112 through § 3.2-4119 (Hemp Program), available at https://law.lis.virginia.gov/vacode/title3.2/chapter41/section3.2-4112/
• Virginia Code § 4.1-600 et seq. (Cannabis Control Act), available at https://law.lis.virginia.gov/vacode/title4.1/chapter6/
• Virginia Cannabis Control Authority Emergency Regulatory Guidance 2026-03 (June 15, 2026), available at https://www.cannabiscontrol.virginia.gov
• House Bill 2312 (2021) - Adult-Use Cannabis Legalization, full text at https://lis.virginia.gov/cgi-bin/legp604.exe?211+sum+HB2312
• Virginia Department of Agriculture and Consumer Services Hemp Program, information and licensing data at https://www.vdacs.virginia.gov/plant-industry-services-hemp.shtml
• Hometown Hero CBD v. Texas Department of State Health Services, 5th Circuit Court of Appeals Case No. 21-50826 (2023), available at https://www.ca5.uscourts.gov
• U.S. Hemp Roundtable policy resources and state-by-state hemp regulations at https://www.hempsupporter.com
• Cannabis Regulators Association best practices for hemp-derived cannabinoid regulation at https://www.cannabisregulators.org
• Virginia NORML policy positions and advocacy updates at https://www.vanorml.org
• Marijuana Moment coverage of Virginia hemp enforcement at https://www.marijuanamoment.net